ArticleInternational journal of general medicine2026
Association of Serum Chitinase-3-Like Protein 1 with Liver Fibrosis Severity in Autoimmune Liver Diseases.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Autoimmune liver diseases (AILDs) require precise fibrosis staging, but current non-invasive tools are limited. This study aimed to evaluate the diagnostic performance of serum chitinase-3-like protein 1 (CHI3L1) for liver fibrosis in AILDs. Methods: This retrospective cohort study consecutively enrolled 226 AILDs patients (including those with autoimmune hepatitis, primary biliary cholangitis, and overlap syndrome) and 40 healthy controls. Cohort 1 (n=112) underwent liver biopsy (Scheuer staging). Cohort 2 (n=114) underwent liver stiffness measurement (LSM) by transient elastography, with no overlap between cohorts. Diagnostic performance was evaluated using receiver operating characteristic (ROC) curve analysis and compared with aspartate aminotransferase-to-platelet ratio index (APRI) and the fibrosis-4 index (FIB-4). Multivariable binary logistic regression adjusted for histological inflammation identified independent predictors of advanced fibrosis. Results: Serum CHI3L1 levels increased significantly with advancing histological (S0-1: 50.6 ng/mL; S2: 80.8 ng/mL; S3-4: 156.3 ng/mL; Conclusion: CHI3L1 level is independently associated with advanced liver fibrosis and shows good diagnostic performance for both significant and advanced liver fibrosis. It is a valuable non-invasive biomarker to supplement existing fibrosis assessment strategies, pending validation across individual AILDs subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.